7 August 2026
Eli Lilly shares climb after stronger revenue outlook driven by obesity drugs
Eli Lilly (NYSE:LLY) rose more than 5% in pre-market trading on Wednesday after the pharmaceutical company increased its full-year revenue guidance, supported by continued strong demand for its blockbuster diabetes and weight-loss treatments. The revised outlook outweighed an earnings-per-share miss for the second quarter, as investors focused on accelerating sales growth and improved profitability expectations.
About this report
Downunder Voices provides an independently written summary and community perspective based on information published by the original source. The original publisher remains responsible for its reporting.
Join our community
Follow Downunder Voices
Join thousands of readers following news and community stories from Australia, New Zealand and the Pacific.
